SPTBN1 (F7N2A) Rabbit mAb #87122
- WB
- IP
- F
Supporting Data
| REACTIVITY | H Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 270 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Flow Cytometry (Fixed/Permeabilized) | 1:100 - 1:400 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
SPTBN1 is involved in cell growth and development (particularly in brain) via the TGF-β/Smad signaling pathway (3,4). SPTBN1 knockout mice show defects in cortical organization, developmental delay, and behavioral deficiencies (3), and variants in human SPTBN1 have been strongly implicated in intellectual disabilities and autism (4). Aberrant expression of SPTBN1 in various cell and tissue types has been shown in cancer development and progression, particularly ovarian, breast, and liver cancers (5-8). SPTBN1 plays an anticancer role in many tumor types. It assists in chemotherapeutic resistance and decreases the migration ability of tumor cells (5,6), highlighting its role in metastatic tumor progression and its potential as a pharmaceutical target (7-9). Recent work has shown that SPTBN1 is important for controlling CAR-T cell migration targeting tumors (10).
- Yang, P. et al. (2021) Int J Biol Sci 17, 32-49.
- Tang, W. et al. (2023) BMC Cancer 23, 303.
- Cousin, M.A. et al. (2021) Nat Genet 53, 1006-1021.
- Rosenfeld, J.A. et al. (2021) Am J Med Genet A 185, 2037-2045.
- Chen, M. et al. (2020) Aging (Albany NY) 12, 10896-10911.
- Wu, H. et al. (2021) Eur J Pharmacol 909, 174401.
- Chen, S. et al. (2022) Cell Mol Gastroenterol Hepatol 13, 949-973.e7.
- Lin, L. et al. (2021) Theranostics 11, 4232-4250.
- Rao, S. et al. (2021) Sci Transl Med 13, eabk2267.
- Hong, Y. et al. (2023) Nat Immunol 24, 1007-1019.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.